Seagen announces results from phase 2 clinical trial of adcetris® (brentuximab vedotin) with novel immunotherapy combination in patients with advanced- and early-stage classical hodgkin lymphoma

Bothell, wash.--( business wire )--seagen inc. (nasdaq: sgen) today announced results from two parts of a phase 2 trial (sgn35-027) evaluating adcetris® (brentuximab vedotin) in combination with the pd-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (an+ad) for the frontline treatment of patients with classical hodgkin lymphoma (chl). part b of the trial evaluated patients with advanced-stage disease and was presented as an oral presentation, and part c evaluated patients with early-stage disease and was presented as a poster at the 64th american society of hematology (ash) annual meeting and exposition in new orleans.
SGEN Ratings Summary
SGEN Quant Ranking